Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 3/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.43 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.40 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.40 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3400566 | 1.00 | TBK1 (0.45) | TBK1GPR119SMARCA2SMARCA4PBRM1 | |
| SCHEMBL1467568 | 0.89 | TBK1 (0.47) | TBK1GPR119SMARCA2SMARCA4PBRM1 | |
| SCHEMBL1467567 | 0.89 | TBK1 (0.47) | TBK1GPR119SMARCA2SMARCA4PBRM1 | |
| SCHEMBL5748844 | 0.88 | GSK3B (0.40) | TBK1 | |
| SCHEMBL1467803 | 0.83 | TBK1 (0.47) | TBK1GPR119SMARCA2SMARCA4PBRM1 | |
| SCHEMBL1467800 | 0.83 | TBK1 (0.47) | TBK1GPR119SMARCA2SMARCA4PBRM1 | |
| SCHEMBL1470077 | 0.82 | TBK1 (0.43) | TBK1GPR119SMARCA2SMARCA4PBRM1 | |
| SCHEMBL1470076 | 0.82 | TBK1 (0.43) | TBK1GPR119SMARCA2SMARCA4PBRM1 | |
| SCHEMBL1468233 | 0.82 | TBK1 (0.44) | TBK1GPR119SMARCA2SMARCA4PBRM1 | |
| SCHEMBL1468232 | 0.82 | TBK1 (0.44) | TBK1GPR119SMARCA2SMARCA4PBRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732444-B2 | 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| EP-1701944-B1 | 2-(AMINO-SUBSTITUTED)-4-ARYL PYRAMIDINES AND RELATED COMPOUNDS USEFUL FOR TREATING INFLAMMATORY DISEASES | MILLENNIUM PHARM INC (US) | 2009-07-29 | — | — | EP | disclosed |
| US-20060040968-A1 | 2-(Amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040968-A1 | 2-(Amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases | PRKCZ, PRKCQ, PRKCE | TBK1 64/4885GPR119 866/4885SMARCA2 3069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.